{"product_id":"duralock-catheter-locking-solution","title":"DuraLock - Catheter Locking Solution","description":"\u003cp\u003eStudies have demonstrated that Trisodium Citrate (TSC) is highly effective as a catheter locking solution.\u003csup\u003e1,2,3,4\u003c\/sup\u003e In addition to being an anticoagulant, TSC has demonstrated antibacterial activity across a broad spectrum of microbes.\u003csup\u003e1,2\u003c\/sup\u003e Another study, commenting on TSC’s anticoagulant character, found a dramatically reduced incidence of thrombolytic intervention in tunnelized hemodialysis catheters.\u003csup\u003e1\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e* Most importantly and most recently, Weijmer, et al \u003csup\u003e4\u003c\/sup\u003e, in a multi-centered, prospective, randomized comparison with heparin and TSC, demonstrated clear superiority of TSC over heparin.\u003c\/p\u003e\n\u003ch3\u003eDURALOCK-C OVER HEPARIN\u003c\/h3\u003e\n\u003cp\u003eCentral venous catheters are usually locked with heparin after treatment. Clinical practice and leading publications show that heparin promotes the growth of biofilm in the catheter and promotes the growth of bacteria.(2) Heparin also generates bleeding risks after catheter insertion and after catheter locking.\u003cbr\u003e\nBased on our long experience, and on our leading contacts with preeminent physicians, we developed DuraLock-C™.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDuraLock-C\u003c\/strong\u003e™ is a concentrated trisodium citrate solution, which has been shown to greatly reduce the incidence of catheter related infections.\u003csup\u003e1,4\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDuraLock-C\u003c\/strong\u003e™ prevents catheter related clotting\u003csup\u003e1,3\u003c\/sup\u003e, maintaining efficient blood flow rates. Clinical practice shows a reduction of at least 70% of the use of thrombolitic agents like Urokinase\/TPA.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDuraLock-C\u003c\/strong\u003e™ prevents the formation of catheter lumen biofilm. Biofilm contributes to catheter related bacteremia.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFeatures \u0026amp; Benefits\u003cbr\u003e\n\u003c\/strong\u003eFully Sterile Tyvek® Pouches Reduces the risk of nosocomial infection, in comparison to glass vials and fluid path only syringe packaging.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eImproved Catheter Patency\u003c\/strong\u003e\u003cbr\u003e\n(30% and 46.7% Concentration)\u003cbr\u003e\nFewer catheter withdrawals due to complications. \u003csup\u003e1, 2\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eReduced Infections\u003c\/strong\u003e\u003cbr\u003e\nLower rate of catheter-related bacteremia. \u003csup\u003e1, 2, 3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeedleless\u003c\/strong\u003e\u003cbr\u003e\nPre-filled syringes and luer lock vials eliminate the need for cumbersome needle withdrawal.\u003cbr\u003e\nEconomical (4% Concentration)\u003cbr\u003e\nReduces the cost of interdialytic anticoagulation by as much as 85%. \u003csup\u003e4\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEfficient\u003c\/strong\u003e\u003cbr\u003e\nPouched syringes save nursing time treating patients coming off dialysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Findings (*Weijmer, et al \u003csup\u003e4\u003c\/sup\u003e )\u003c\/th\u003e\n\u003cth\u003eTSC (30%)\u003c\/th\u003e\n\u003cth\u003eHeparin (5,000 units)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCatheter withdrawn due to complications\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCatheter related bacteremia per 1,000 patient days\u003c\/td\u003e\n\u003ctd\u003e1.1%\u003c\/td\u003e\n\u003ctd\u003e4.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeaths due to catheter related bacteremia\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eDuraLock-C Pre-Filled Syringes\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth width=\"110\"\u003eOrdering Code\u003c\/th\u003e\n\u003cth width=\"301\"\u003eDescription\u003c\/th\u003e\n\u003cth width=\"89\"\u003eUOM\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePFDLC504\u003c\/td\u003e\n\u003ctd\u003eDURALOCK-C PRE-FILLED SYRINGE 4.0%\u003c\/td\u003e\n\u003ctd\u003e30 \/ BOX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePFDLC546\u003c\/td\u003e\n\u003ctd\u003eDURALOCK-C PRE-FILLED SYRINGE 46.7%\u003c\/td\u003e\n\u003ctd\u003e30 \/ BOX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eReferences\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\u003ccite\u003eAsh SR, Mankus RA, Sutton JM, Criswell RE, Crull CC, Velasquez KA, Smeltzer BD, Ing TS: Concentrated sodium citrate (23%) for catheter lock. Hemodial Int 4: 22-31, 2000\u003c\/cite\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ccite\u003eWeijmer MC, Debets-Ossenkopp YJ, van de Vondervoort FJ, ter Wee PM: Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 17:2189-2195, 2002\u003c\/cite\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ccite\u003eBayés B, Bonal J, Romero R: Sodium citrate for filling haemodialysis catheters. Nephrol Dial Transplant\u003cbr\u003e\n14: 2532-2533, 1999\u003c\/cite\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ccite\u003eWeijmer MC, et al: Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J. Am. Soc. Nephrol., 16: 2769 – 2777, 2005\u003c\/cite\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\n\u003cp\u003eIntroducing DuraLock-C Pre filled Syringes, packed in fully sterile sets. In addition to the already proven benefits of trisodium citrate catheter lock solution, pre filled syringes increase overall procedural efficiency and remove the risk from needle sticks and glass particle injections. Furthermore, while other prefilled cellophane wrapped syringes offer a sterile pathway only, we take ours a step further and fully sterilize the outside of the syringe as well as the fluid path.\u003c\/p\u003e\n","brand":"I-Surgical","offers":[{"title":"Default Title","offer_id":45377568210991,"sku":null,"price":0.0,"currency_code":"NAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0764\/9964\/8559\/files\/15324_untitled-design-30.png?v=1779383241","url":"https:\/\/i-surgical.com\/products\/duralock-catheter-locking-solution","provider":"I-Surgical","version":"1.0","type":"link"}